

Our Ref: NG/RM/26031
Date: 24th February 2026

Nicola Griffiths
Deputy Director of Governance
North Staffordshire Combined Healthcare NHS Trust
Lawton House
Bellringer Road
Trentham
ST4 8HH

Reception: 0300 123 1535

Dear

Freedom of Information Act Request

I am writing in response to your e-mail of the 29th January 2026. Your request has been processed using the Trust's procedures for the disclosure of information under the Freedom of Information Act (2000).

Requested information:

1. The number of patients under the Trust's care with a recorded diagnosis of Dravet syndrome in each month of 2025 (January–December). Patients may be counted in more than one month. Likely coded as ICD-10 code G40.3 or SNOMED code 230437002.
 - a. Patient numbers segmented by age:
 - i. 2-8 years old
 - ii. 9-17 years old
 - iii. 18 years+

Please see Appendix 1 attached.

2. The number of patients under the Trust's care with a recorded diagnosis of Lennox-Gastaut syndrome in each month of 2025 (January-December). Patients may be counted in more than one month. Likely coded as ICD-10 code G40.4 or SNOMED code of 230418006.
 - a. Patient numbers segmented by age:
 - i. 2-8 years old
 - ii. 9-17 years old
 - iii. 18 years+

Please see Appendix 1 attached.

3. The number of patients under the Trust's care who have been treated with fenfluramine in 2025 (January-December), separated by month
 - a. Patient numbers segmented by age: **0**
 - i. 2-8 years old.

- ii. 9-17 years old.
 - iii. 18 years+.
 - b. For these patients, how many of them had a diagnosis of:
 - i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002. **N/A**
 - ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006. **N/A**
 - c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. **N/A**
 - d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. **N/A**
4. The number of patients under the Trust’s care who have been treated with cannabidiol in 2025 (January-December), separated by month
- a. Patient numbers segmented by age: **0**
 - i. 2-8 years old
 - ii. 9-17 years old
 - iii. 18 years+
 - b. For these patients, how many of them had a diagnosis of:
 - i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002. **N/A**
 - ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006. **N/A**
 - c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. **N/A**
 - d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. **N/A**
5. The number of patients under the Trust’s care who have been treated with cenobamate in in 2025 (January-December), separated by month. **0**
- a. Patient numbers segmented by age:
 - i. 2-8 years old
 - ii. 9-17 years old
 - iii. 18 years+

- b. For these patients, how many of them had a diagnosis of:
 - i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002. **N/A**
 - ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006. **N/A**
 - c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. **N/A**
 - d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. **N/A**
6. The number of patients under the Trust’s care who have been treated with rufinamide in 2025 (January-December), separated by month. **0**
- a. Patient numbers segmented by age:
 - i. 2-8 years old.
 - ii. 9-17 years old.
 - iii. 18 years+.
 - b. For these patients, how many of them had a diagnosis of:
 - i. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006. **N/A**
 - c. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. **N/A**
7. The number of patients under the Trust’s care who have been treated with stiripentol in 2025 (January-December), separated by month. **0**
- a. Patient numbers segmented by age:
 - i. 2-8 years old.
 - ii. 9-17 years old.
 - iii. 18 years+.
 - b. For these patients, how many of them had a diagnosis of:
 - i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002. **N/A**
 - ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006. **N/A**
 - c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications

were recorded for these patients during the year, and the number of patients associated with each medication. **N/A**

- d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. **N/A**

Good to know questions:

8. The number of patients under the Trust's care who have been treated with clobazam in 2025 (January-December), separated by month
- a. Patient numbers segmented by age:
 - i. 2-8 years old
 - ii. 9-17 years old
 - iii. 18 years+

Please see Appendix 1 attached.

- b. For these patients, how many of them had a diagnosis of:
 - i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002. **1**
 - ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006. **0**
- c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. **0**
- d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. **N/A**

9. The number of patients under the Trust's care who have been treated with sodium valproate in 2025 (January-December), separated by month
- a. Patient numbers segmented by age:
 - i. 2-8 years old
 - ii. 9-17 years old
 - iii. 18 years+

Please see Appendix 1 attached.

- b. For these patients, how many of them had a diagnosis of:
 - i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002. **0**
 - ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006. **0**

- c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. **N/A**
 - d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. **N/A**
10. The number of patients under the Trust’s care who have been treated with topiramate in 2025 (January-December), separated by month
- a. Patient numbers segmented by age:
 - i. 2-8 years old
 - ii. 9-17 years old
 - iii. 18 years+

Please see Appendix 1 attached.

- b. For these patients, how many of them had a diagnosis of:
 - i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002. **0**
 - ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006. **0**
 - c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. **N/A**
 - d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. **N/A**
11. The number of patients under the Trust’s care who have been treated with lamotrigine in 2025 (January-December), separated by month
- a. Patient numbers segmented by age:
 - i. 2-8 years old
 - ii. 9-17 years old
 - iii. 18 years+

Please see Appendix 1 attached.

- b. For these patients, how many of them had a diagnosis of:
 - i. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006. **0**

- c. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. **0**

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review of the management of your request. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Dr Buki Adeyemo, Chief Executive, North Staffordshire Combined Healthcare Trust, Trust Headquarters, Lawton House, Bellringer Road, Trentham, ST4 8HH. If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

Yours sincerely



Nicola Griffiths
Deputy Director of Governance

1. The number of patients under the Trust's care with a recorded diagnosis of Dravet syndrome in each month of 2025 (January–December). Patients may be counted in more than one month. Likely coded as ICD-10 code G40.3 or SNOMED code 230437002.

a. Patient numbers segmented by age:

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
i. <2 years old	0	0	0	0	0	0	0	0	0	0	0	0
ii. 2-8 years old	0	0	0	0	0	0	0	0	0	0	0	0
iii. 9-17 years old	0	0	0	0	0	0	0	0	0	0	0	0
iv. 18 years+	0	0	1	1	1	0	0	0	0	1	1	0

2. The number of patients under the Trust's care with a recorded diagnosis of Lennox-Gastaut syndrome in each month of 2025 (January–December). Patients may be counted in more than one month. Likely coded as ICD-10 code G40.4 or SNOMED code of 230418006.

a. Patient numbers segmented by age:

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
i. <2 years old	0	0	0	0	0	0	0	0	0	0	0	0
ii. 2-8 years old	0	0	0	0	0	0	0	0	0	0	0	0
iii. 9-17 years old	1	1	1	1	1	0	1	1	1	1	1	1
iv. 18 years+	0	0	0	0	0	0	0	0	0	0	0	0

8. The number of patients under the Trust's care who have been treated with clobazam in 2025 (January–December), separated by month

a. Patient numbers segmented by age:

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
i. <2 years old	0	0	0	0	0	0	0	0	0	0	0	0
ii. 2-8 years old	0	0	0	0	0	0	0	0	0	0	0	0
iii. 9-17 years old	0	0	0	0	0	0	0	0	0	0	0	0
iv. 18 years+	0	0	0	0	0	0	0	0	0	1	1	0

9. The number of patients under the Trust's care who have been treated with sodium valproate in 2025 (January–December), separated by month

a. Patient numbers segmented by age:

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
i. <2 years old	0	0	0	0	0	0	0	0	0	0	0	0
ii. 2-8 years old	0	0	0	0	0	0	0	0	0	0	0	0
iii. 9-17 years old	0	0	0	0	0	0	0	0	0	0	0	0
iv. 18 years+	0	0	0	0	0	1	1	0	0	0	0	0

10. The number of patients under the Trust's care who have been treated with topiramate in 2025 (January–December), separated by month

a. Patient numbers segmented by age:

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
i. <2 years old	0	0	0	0	0	0	0	0	0	0	0	0
ii. 2-8 years old	0	0	0	0	0	0	0	0	0	0	0	0
iii. 9-17 years old	0	0	0	0	0	0	0	0	0	0	0	0
iv. 18 years+	2	2	1	0	0	0	0	1	1	1	0	0

2 patients over the above months

11. The number of patients under the Trust's care who have been treated with lamotrigine in 2025 (January–December), separated by month

a. Patient numbers segmented by age:

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
i. <2 years old	0	0	0	0	0	0	0	0	0	0	0	0
ii. 2-8 years old	0	0	0	0	0	0	0	0	0	0	0	0
iii. 9-17 years old	0	0	0	0	0	0	0	0	0	0	0	0
iv. 18 years+	1	1	1	1	1	1	1	0	1	0	0	0